β3-Adrenoceptor Antagonist SR59230A Attenuates the Imbalance of Systemic and Myocardial Oxygen Transport Induced by Dopamine in Newborn Lambs by Gill, Richdeep S. et al.
Clinical Medicine Insights: Cardiology 2012:6 45–51
doi: 10.4137/CMC.S8654
This article is available from http://www.la-press.com.
© the author(s), publisher and licensee Libertas Academica Ltd.
This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited.
Open Access
Full open access to this and 
thousands of other papers at 
http://www.la-press.com. OriginAL reSeArCh
Clinical Medicine insights: Cardiology 2012:6  45
Clinical Medicine insights: Cardiology
β3-Adrenoceptor Antagonist sR59230A Attenuates  
the Imbalance of systemic and Myocardial Oxygen  
Transport Induced by Dopamine in newborn Lambs
richdeep S. gill1, Po-Yin Cheung1,2, Xiaoyang Yu2, Mohammed Al Aklabi1, Jeevan nagendran1,  
Luis g. Quinonez1, Ying Qian Li2, John Miller1, David B. ross1, ivan M. rebeyka1 and Jia Li2
1Department of Surgery, University of Alberta, edmonton, Alberta. 2Department of Pediatrics, University of Alberta, 
edmonton, Alberta. Corresponding author email: jia.li@albertahealthservices.ca
Abstract
Background: In neonates, the increase in O2-delivery (DO2) by dopamine is offset by a greater increase in O2-consumption (VO2). This 
has been attributed to β3-adrenergic receptors in neonatal brown fat tissue. β3 receptors in the heart have negative inotropic properties. 
We evaluated the effects of SR59230A, a β3-antagonist, on the balance of systemic and myocardial O2-transport in newborn lambs 
treated with dopamine.
Methods: Lambs (2–5 days old, n = 12) were anesthetized and mechanically ventilated. Heart rate (HR) and rectal temperature were 
monitored. VO2 was measured by respiratory mass spectrometry and cardiac output (CO) by a pulmonary artery transonic   flowmeter. 
Arterial, jugular bulb venous and coronary sinus blood gases and lactate were measured to calculate DO2, O2 extraction ratio (ERO2), 
  myocardial O2 and lactate extraction ratios (mERO2, mERlac). After baseline measurements, lambs were randomized to receive SR59230A 
at 5 mg/kg iv (SRG) or placebo. Both groups received incremental doses of a dopamine infusion (0–5–10–15–20 mcg/kg/min) every 
15 min. Measurements were repeated at the end of each dose.
Results: After SR59230A infusion, CO and HR trended to decrease (P = 0.06), but no significant changes occurred in other parameters. 
Over the incremental doses of dopamine, temperature increased in both groups (P , 0.0001) but to a lesser degree in SRG (P = 0.004). 
CO and HR increased (P = 0.005 and 0.04) and similarly in both groups (P . 0.1). DO2 trended to a small increase (P = 0.08). 
VO2 increased in both groups (P , 0.0001) but to a lesser degree in SRG (P , 0.0001). As a result, ERO2 increased in both groups 
(P , 0.0001), but to a lesser degree in SRG (P , 0.0001). mERO2 was lower in SRG (P = 0.01) with a faster increase (P , 0.0001). 
mERlac was higher in SRG (P = 0.06) with a faster decrease (P = 0.04).
Conclusion: Although SR59230A tends to induce an initial drop in CO, it significantly attenuates the rise in VO2 and hence the imbal-
ance of systemic and myocardial O2 transport induced by dopamine at higher doses. Studies are warranted to examine the effect of 
SR59230A in cases of cardiac dysfunction and increased VO2, observed after cardiac surgery.
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Introduction
Dopamine, a precursor in the endogenous synthesis 
of  norepinephrine,  is  the  most  commonly  used 
medication  to  provide  cardiovascular  support  in 
critically ill patients with low cardiac output state, via 
the stimulation of β1 and β2 adrenergic receptors.1,2 
Often, these patients have impaired balance of oxygen 
transport  and  poor  tissue  perfusion.  Therefore,  in 
addition to improved cardiovascular state, the major 
goal of therapy in these patients is to improve the 
balance  of  systemic  oxygen  transport  and  tissue 
oxygenation  by  increasing  systemic  O2  delivery 
(DO2) relative to changes in systemic O2 consumption 
(VO2). In adult humans and animal experiments, the 
increase in DO2 induced by catecholamines is about 
10-fold of the increase in VO2.3–5
However, in neonates, in contrast to that observed 
in  adults  and  older  children,  dopamine  worsens 
the  balance  of  systemic  oxygen  transport  by  a 
greater  increase  in  VO2  than  DO2  as  shown  after 
cardiopulmonary bypass surgery.6 In neonatal lambs, 
dobutamine, a synthetic analog of dopamine, increases 
VO2 by 7–12 fold compared to older lambs, with a 
similar  increase  in  DO2.  The  substantial  increase 
in VO2 has been attributed to the abundant brown 
adipose tissue in neonates, which contains plentiful 
α, β1 and β3 adrenergic receptors.7,8 Stimulation of 
these  receptors  by  catecholamines  leads  to  non-
shivering  thermogenesis  and  a  substantial  increase 
in VO2.7,9,10 It has been shown that selective α1, β1 
or β2-adrenoceptor blockade in newborn lambs does 
not affect the increases in VO2 or DO2 induced by 
dobutamine, but the combined adrenoceptor blockades 
markedly attenuated both VO2 and DO2.3
β3-adrenergic receptor was discovered in 1970s 
and 1980s from pharmacological studies of rat adipo-
cyte function, and is now known to be richly present 
in brown adipose tissue controlling of thermogen-
esis and energy balance.8,11,12 It has been shown that 
dopamine exerts a thermogenic effect on the brown 
adipose tissue and increases VO2 in rats.10 Selective 
β3-adrenoceptor antagonist, SR59230A,13 has been 
reported to down-regulate uncoupling protein-1 and 
norepinephrine induced cAMP accumulation,13,14 thus 
reduce thermogenesis in brown fat tissue in lambs.15 
In  addition,  it  has  been  found  that  β3-adrenergic 
receptors  in  the  heart  have  negative  inotropic 
  properties.  This  has  led  to  research  investigating 
potential   therapeutic applications to enhance cardiac 
  contractility by blocking β3-adrenergic receptors in 
heart failure.16
Therefore, we hypothesized that SR59230A may 
attenuate the increase in VO2 induced by dopamine, 
and maintain the inotropic effect, thus cardiac output 
(CO) and DO2, thereby improving the balance of sys-
temic and myocardial oxygen transport in neonatal 
lambs.
Methods and Materials
Animal preparation
All experiments were conducted in accordance with 
guidelines and by approval of the Animal Care and 
Use  Committee  (Health  Science),  University  of 
Alberta.  Twelve  mixed-breed  newborn  lambs  1  to 
5 days of age weighing 2.5 to 5.0 kg were obtained 
from a local farm. Anesthesia was induced with iso-
flurane (2%–3%). After induction, isoflurane inhala-
tion was ceased, and anesthesia was maintained with 
continuous i.v. infusion of fentanyl (5–10 µg/kg/h), 
midazolam  (0.1–0.2  mg/kg/h)  and  pancuronium 
(0.05–0.1 mg/kg/h). Animals were intubated with a 
cuffed endotracheal tube to prevent any air leaks, and 
ventilated with FiO2 0.3 and volume-cycled   ventilation 
(SERVO VENTILATOR 300, Siemens Medical Sys-
tems, Solna, Sweden), a tidal volume of 10 mL/kg, 
rates of 20–30 breaths/min, and PEEP of 4 cm H2O. 
Systemic arterial blood gases were measured (iStat, 
Abbott  Laboratories.  Abbott  Park,  IL  USA)  and 
ventilation was adjusted to maintain pH 7.35–7.45, 
PaO2 100–140 mmHg, and PaCO2 at 35–40 mmHg, 
while base deficits .2 mmol/L were corrected with 
22 mEq/L NaHCO3. Blood that had been collected 
from an adult donor lamb was used for blood transfu-
sion at a rate of 20 to 30 mL/h.
Left femoral arterial, superior vena cava, coronary 
sinus catheters were inserted to monitor pressures, 
blood gases and to administer fluids and medications. 
Heart rate was measured (Hewlett Packard, Palo Alto, 
CA). Maintenance fluids consisted of 5% dextrose-
saline at 10 mL/kg/h. Temperature was monitored by 
a rectal thermometer, and maintained above 37 °C by 
a heating pad and warm blankets, which were kept 
constant during the experimental period. A sternotomy 
was performed and the ductus arteriosus was ligated. 
An 8–10 mm diameter ultrasonic perivascular flow 
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was  placed  around  the  main  pulmonary  artery  to 
continuously measure CO.
VO2  was  continuously  measured  using  respira-
tory mass spectrometry (AMIS2000 Innovision A/S, 
Odense,  Denmark). This  is  highly  sensitive,  accu-
rate and rapid method to allow simultaneous mea-
surements  of  multiple  gas  fractions,  and  has  been 
described previously.17 Stroke volume was calculated 
as CO/heart rate. DO2 was calculated as CO times 
arterial  oxygen  content  (CaO2).  Oxygen  extraction 
ratio  (ERO2)  was  calculated  as VO2/DO2. All  sys-
temic hemodynamic and oxygen transport variables 
were indexed by weight as appropriate.
Myocardial oxygen and lactate extraction ratios 
(mERO2,  mERlac,  respectively)  were  calculated 
using standard equations:
mEO2 = (CaO2 - CcsO2)/CaO2
mERlac =   (arterial lactate concentration - coronary 
sinus lactate concentration)/ 
arterial lactate concentration
where  CcsO2  indicates  coronary  sinus  oxygen 
content.
experimental protocol
Lambs were randomized into two groups (n = 6 each) 
after a period of stabilization and baseline measurements 
of hemodynamics, oxygen transport and central tem-
perature were obtained. Subsequently, the experimental 
(SR group) received an i.v. infusion of SR59230A at 
5 mg/kg dissolved firstly in 0.5 mL DMSO, and then 
in 10 mL saline and an equal volume of the DMSO and 
saline, respectively, over 5 min. After 30 min, incre-
mental dopamine i.v. infusions starting from 5 were 
increased  to  10,  15,  and  20  µg/kg/min  sequentially 
every 15 minutes. Measurements were repeated before 
dopamine infusion and at the end of each dose of dop-
amine in both groups. At the end of the study, an over 
dose of phenobarbital was given for euthanasia.
Statistical analysis
Data are expressed as mean ± SD. Mixed linear regres-
sion for repeated measures was used to compare the 
variables before and after SR59230A or saline infusion 
between the two groups. It was also used to compare 
the different levels of the variables and their trends of 
changes between groups over the incremental increases 
of dopamine, with analyses of the effects of group (Pgroup) 
and dose (Pdose) and the interaction between dose and 
group (Pgroup*dose). All data analysis was performed using 
SAS statistical software version 9.2 (SAS Institute Inc). 
A P value ,0.05 indicates a statistical significance.
Results
There were no significant differences in age (mean 
3 days old) and weight (4.0 ± 1.0 kg vs. 3.7 ± 0.6 kg) 
between the SR and Control groups, respectively.
Changes of the variables before  
and after Sr 59230A/saline infusion  
in the two groups (Table 1 and Fig. 1)
All hemodynamic and oxygen transport variables were 
not significantly different at baseline between the two 
groups.  Thirty  minutes  following  SR59230A  infu-
sion, temperature and mean arterial pressure remained 
unchanged and were not different from those of Con-
trol group. Heart rate trended to decrease from 237 ± 33 
beats/min to 202 ± 7 beats/min in SR group (P = 0.08). 
CO trended to decrease from 167 ± 31 ml/min/kg to 
123 ± 8 mL/min/kg in SR group (P = 0.08). Stroke vol-
ume remained similar after SR59230A infusion within 
both groups. DO2, VO2, ERO2, mERO2 and mERlac did 
not change significantly in SR group. There were no sig-
nificant changes in all the variables in Control group.
Changes of the variables over the 
incremental infusion of dopamine  
in the two groups (Table 1 and Fig. 1)
Over  incremental  doses  of  dopamine,  temperature 
increased significantly in both groups (Pdose , 0.0001); 
the  rate  of  temperature  increase  was  signifi-
cantly less in SR group compared to Control group 
(Pdose*group , 0.005). There was no significant change 
in mean arterial pressure in either SR or Control group. 
Heart  rate  significantly  increased  in  both  groups 
(Pdose , 0.05) to a similar degree (Pdose*group . 0.10). CO 
significantly increased in both groups (Pdose , 0.005) 
to a similar degree (Pdose*group . 0.10). There was no 
significant change in stroke volume in both groups. 
DO2 trended to a small increase (Pdose = 0.08) due to a 
small but significant decrease in hemoglobin in both 
groups (Pdose =  0.04). VO2 increased   significantly in 
both groups (Pdose , 0.0001); however, the rate of  VO2 
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increase was significantly less in SR group compared to 
Control group (Pdose*group , 0.0001). As a result, ERO2 
increased significantly in both groups (Pdose , 0.0001). 
The rate of overall increase in ERO2 was significantly 
less in SR group (Pdose*group , 0.0001), and it started 
to decrease at the incremental dose of dopamine from 
10 to 20 ug/kg/min. mERO2 did not increase signifi-
cantly in both groups (P . 010). mERO2 was signifi-
cantly lower in SR group (Pgroup = 0.01), with faster 
increase  in  SR  groups  compared  to  Control  group 
(P  ,  0.0001).  mERlac  decreased  significantly  in 
both groups (P = 0.04). mERlac levels trended to be 
higher (P = 0.08) with faster decrease over the doses 
of   dopamine (P = 0.04).
Discussion
This  study  demonstrates  that  in  newborn  lambs, 
SR59230A, a selective β3-adrenoreceptor antagonist, 
significantly attenuated the imbalance in systemic oxy-
gen transport seen with incremental dopamine infusion. 
These increases in VO2 levels were significantly atten-
uated by SR59230A, whilst the increases in DO2 were 
not significantly different between the two groups. As a 
result, the balance of systemic and myocardial oxygen 
Table 1. Mean ± SD values of temperature, hemodynamics, and oxygen transport during the study protocol.
pre-sR Dopamine dose (μg/kg/min)
0 5 10 15 20
Temperature (°C)
  Control group 37.4 ± 1 37.7 ± 1 38.2 ± 1   38.5 ± 1 38.9 ± 1 39.1 ± 1‡
  Sr group 38.1 ± 1 38.6 ± 1 38.9 ± 1   39.1 ± 1 39.3 ± 1 39.3 ± 1‡,§
MAP (mmhg)
  Control group    65 ± 14    61 ± 14    61 ± 14    62 ± 10    62 ± 10    67 ± 10
  Sr group    73 ± 16    78 ± 7    75 ± 8    70 ± 6    75 ± 10    73 ± 12
hr (beats/min)
  Control group  223 ± 32  230 ± 28  234 ± 29    227 ± 21  235 ± 22  242 ± 26
  Sr group  237 ± 33  202 ± 16†  206 ± 17    205 ± 13  206 ± 15  208 ± 15
hb (g/dL)
  Control group   8.0 ± 1.1   8.1 ± 1.3   7.8 ± 1.2   7.5 ± 1.0   7.4 ± 1.1   7.4 ± 1.2‡
  Sr group   8.1 ± 1.4   8.1 ± 1.2   7.9 ± 0.8   7.6 ± 0.9   7.5 ± 1.0   7.6 ± 1.2‡
CO (mL/min/kg)
  Control group  169 ± 44  158 ± 21  158 ± 34    170 ± 42  178 ± 42  176 ± 55
  Sr group  167 ± 31  123 ± 21†  124 ± 24    132 ± 34  137 ± 38  147 ± 44
SV (mL/beat/kg)
  Control group   0.8 ± 0.2   0.7 ± 0.2   0.7 ± 0.2   0.8 ± 0.2   0.8 ± 0.2   0.7 ± 0.2
  Sr group   0.7 ± 0.2   0.6 ± 0.1   0.6 ± 0.2   0.7 ± 0.2   0.7 ± 0.2   0.7 ± 0.2
DO2 (mL/min/kg)
  Control group    73 ± 21    70 ± 19    66 ± 17    67 ± 12    68 ± 16    67 ± 18
  Sr group    73 ± 19    54 ± 13    51 ± 6    56 ± 13    59 ± 13    64 ± 16
VO2 (mL/min/kg)
  Control group   11 ± 2.7   11 ± 1.3   11 ± 1.9     12 ± 1.6   13 ± 1.1   14 ± 1.3‡
  Sr group   12 ± 1.4   11 ± 1.9   11 ± 1.9     11 ± 1.7   12 ± 1.8   12 ± 1.9‡,§
erO2
  Control group 0.16 ± 0.03 0.16 ± 0.03 0.17 ± 0.04 0.219 ± 0.03 0.20 ± 0.05 0.23 ± 0.07‡
  Sr group 0.18 ± 0.06 0.20 ± 0.06 0.22 ± 0.05   0.21 ± 0.08 0.20 ± 0.06 0.19 ± 0.06‡,§
merO2
  Control group 0.61 ± 0.19 0.61 ± 0.10 0.65 ± 0.12   0.63 ± 0.09 0.67 ± 0.05 0.69 ± 0.06
  Sr group 0.54 ± 0.19 0.55 ± 0.09 0.57 ± 0.06   0.60 ± 0.08 0.64 ± 0.08 0.67 ± 0.09§
merlac
  Control group 0.07 ± 0.10 0.13 ± 0.19 0.14 ± 0.09   0.04 ± 0.17 0.04 ± 0.22 0.01 ± 0.27
  Sr group 0.10 ± 0.31 0.22 ± 0.27 0.22 ± 0.16   0.10 ± 0.10 0.11 ± 0.20 0.07 ± 0.18§
notes: †P = 0.08 compared to Pre-Sr values; ‡Pdose , 0.05 for the change over incremental doses of dopamine; §Pgroup*dose , 0.05 for the interaction 
between group and dose of dopamine, indicating the difference in the rate of change over incremental doses of dopamine between the two groups.
Abbreviations: MAP, mean arterial pressure; hr, heart rate; CO, cardiac output; SV, stroke volume; DO2, oxygen delivery; VO2, oxygen consumption; 
erO2, oxygen extraction ratio.Clinical Medicine insights: Cardiology 2012:6  49
transport was improved, as indicated by the attenuated 
increase in ERO2, lower mERO2 and higher mERlac.
The  goal  of  dopamine  and  other  catecholamine 
therapy is to improve the balance of systemic oxy-
gen transport by a greater increase in DO2 relative to 
changes in VO2. Both circulatory and metabolic stimu-
lating effects by catecholamines share the same adren-
ergic signaling mechanisms, mainly, β1 and β2 and 
α-adrenergic  receptors.  If  the  circulatory  responses 
to adrenergic stimulation are reduced, or the meta-
bolic response enhanced, the beneficial effects of cat-
echolamines might be abrogated. Such is the case in 
neonatal subjects particularly those with myocardial 
injury and increased VO2 as seen after cardiopulmo-
nary bypass surgery.6 It has been shown that α, β1, 
β2-adrenergic antagonists fail to improve the balance 
of oxygen transport, due to ineffective reduction of 
VO2 when each selectively used, or attenuation of both 
VO2 and DO2 to a similar degree when combined.3
β3-adrenoreceptors  also  have  both  circulatory 
and  metabolic  effects,  but  distinctly  different  from 
other  adrenergic  receptors.  In  terms  of  metabolic 
effect,  β3-adrenergic  receptor  are  richly  present  in 
brown  adipose  tissue.9  Brown  adipose  tissue  gener-
ates  heat  following  stimulation  of  α-,  β1-,  particu-
larly β3-adrenoreceptors by the sympathetic nervous 
system.7  It  plays  an  essential  role  in  non-shivering 
thermogenesis, hence VO2, in newborn humans and 
some in larger mammals including lambs. The ability 
to specifically activate or reduce energy expenditure 
via β3-adrenoreceptor manipulation is of much inter-
est for the thermoregulation in newborns. Using the 
β3-adrenergic agonist Zeneca D7114 increased body 
temperature  in  moderately  hypothermic    Caesarean 
section-delivered  lambs.13  Selective  and  potent 
β3-adrenoreceptor  antagonist  SR59230A  has  been 
shown to down-regulate uncoupling protein-1 and nor-
epinephrine induced cAMP accumulation, thus reduc-
ing thermogenesis in brown adipose tissue in animal 
experiments  including  sheep  models.13–15  Our  find-
ings on the systemic effects of the attenuated rises in 
central body temperature and VO2 in newborn lambs 
treated  with  SR59230A  prior  to  dopamine  infusion 
are  consistent  with  previous  findings  at  tissue  and 
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Figure 1. The changes of (A) heart rate, (B) cardiac output, (c) systemic oxygen delivery (DO2), (D) systemic oxygen consumption (VO2), and (e) oxygen 
extraction ratio (erO2) prior to and following Sr59230A infusion with incremental doses of dopamine. Control group received placebo of saline.
notes: Pdose indicates dopamine dose effect during dopamine infusion; and Pdose*group indicates the difference in the rate of change between the two groups.
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molecular levels.13–15 The improved   balance of systemic 
oxygen transport may, at least partly, contribute the 
improved myocardial oxygen transport as indicated by 
the lower mERO2 and higher mERlac in lambs treated 
with SR59230A be attributed, at least partly, to the 
improved balance of systemic oxygen transport.
Nonetheless,  the  specific  cardiac  effect  of 
SR59230A should also be accounted for. Compared to 
brown adipose tissue, β3-adrenoreceptors in the heart 
have been less extensively studied, but have gained 
increasing interest in recent years. It has been reported 
that β3-adrenoreceptor stimulation exerts a profound 
dose-dependent negative inotropic effect in ventricles 
with  decreased  myocardial  contractility  in  humans 
and  other  species.18–20  Hence,  it  is  suggested  that 
β3-adrenoreceptors serves as a “brake” during sympa-
thetic overstimulation to antagonize β1-adrenoreceptors 
and  β2-adrenoreceptors  in  the  heart.20,21  In  addition, 
β3-adrenoreceptor  stimulation  also  exerts  positive 
chronotropic  effects,  probably  resulted  from  reflex 
mechanisms rather than from a direct stimulation of 
cardiac b3-adrenoceptors.22,23 It might be extrapolated 
that  β3-adrenoreceptor  antagonist  may  increase  or 
maintain the inotropic effect of dopamine, thus myo-
cardial contractility, but at the same time reduce the 
heart rate. As shown in our data, following SR59230A 
infusion, there was an immediate reduction in heart 
rate, but stroke volume was maintained. As a result, 
CO and DO2 decreased.   Nonetheless, during incremen-
tal doses of dopamine infusion, the changes in heart 
rate, CO and stroke volume were not significantly dif-
ferent between the two groups. The lower heart rate 
and CO, thus reduced myocardial workload, might be 
attributable to the better balance of myocardial oxy-
gen transport. It is important to note that, despite an 
initial reduction in heart rate and CO, the greater and 
continuous reduction in VO2 by SR59230A attenuated 
the imbalance of systemic oxygen transport at higher 
doses of dopamine infusion as indicated by the attenu-
ated increase in ERO2.
Limitations
There are several limitations in our study. First, stroke 
volume was used to reflect cardiac contractility. The 
changes in myocardial contractility in the experiment 
may  be  more  accurately  assessed  with  direct  mea-
surement utilizing techniques such as tissue   Doppler 
by  echocardiography24  or  conductance  catheter.25 
  Secondly, myocardial lactate extraction ratio reflects 
the  overall  balance  of  the  complex  production  and 
consumption of lactate by myocardium. A high lactate 
extraction may indicate less lactate production or more 
lactate  consumption,  or  both.  The  exact  mechanism 
can only be shown by direct examination of myocar-
dial   metabolism. Nonetheless, based on the lower myo-
cardial oxygen extraction ratio in lambs treated with 
SR59230A, the less lactate production may be likely 
the case in our study. Thirdly, we did not directly assess 
the regional changes in oxygen consumption in brown 
fat tissue. Therefore, the relationship between VO2 and 
brown fat tissue remains speculative in our study. Forth, 
this is a pilot study in healthy newborn lambs using 
only one dose of SR59230A. A dose response study in 
newborn lambs with myocardial injury and increased 
VO2, such as newborn subjects following cardiopulmo-
nary bypass may provide more detailed and relevant 
information about the effects on SR59230A on VO2 and 
myocardial contractility, thus CO and DO2.
conclusion
Although  β3-adrenoceptor  antagonist  SR59230A 
tends to induce an initial drop in heart rate and CO, 
it  significantly  attenuates  the  increase  in  VO2  and 
hence the imbalance of systemic and myocardial oxy-
gen transport induced by dopamine at higher doses. 
Further studies are warranted to examine the dose 
response effect of SR59230A in subjects with myo-
cardial injury and increased VO2 such as those after 
cardiopulmonary bypass surgery.
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